Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Spatial transcriptomics dissects mechanism of action of the PD-1 targeted IL15-mutein in B16-F10-OVA tumor-bearing mice

ABSTRACT: KD050 is an anti-PD-1/IL-15 bi-functional antibody with strong PD-1 antagonist function, but lower lymphocyte stimulation enabled by a novel mutation on the IL-15. Here, we spatially characterized at RNA level the effect of mKD050 surrogate I in B16-OVA (melanoma) mouse model, in comparison with anti-mPD1 and mouse non-targetKD050 (mntKD050).

ORGANISM(S): Mus musculus

PROVIDER: GSE324814 | GEO | 2026/04/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Spatial transcriptomics dissects mechanism of action of the PD-1 targeted IL15-mutein in B16-F10-OVA tumor-bearing mice

Project description:Spatial transcriptomics dissects mechanism of action of the PD-1 targeted IL15-mutein in B16-F10-OVA tumor-bearing mice

| PRJNA1437103 | ENA

An Engineered IL-15 Cytokine Mutein Fused to an Anti-PD-1 Antibody Improves Intratumoral T Cell Function and Anti-tumor Immunity

Project description:The anti-PD-1 antibody-IL-15 cytokine fusion approach was developed to optimally activate intra-tumoral CD8+ T cells. We engineered a fusion protein of a single, potency-reduced, IL-15 mutein and an anti-PD-1 antibody (αPD1-IL15m). This immunocytokine is designed to deliver PD-1-mediated avidity-driven IL-2/15 receptor stimulation preferentially to PD-1-positive tumor-infiltrating lymphocytes (TILs) while reducing the natural preference of IL-15 for circulating peripheral NK or T cells.

2021-07-13 | GSE160579 | GEO

Dual Activation of CD8+ and CD4+ T cells by a PD-1 targeted IL-15 Mutein in Viral Infection

Project description:Immune checkpoint inhibitors have transformed cancer therapy, yet many patients fail to achieve durable responses, in part due to insufficient T cell reinvigoration. Cytokines remain promising additions to immunotherapy to improve response rates; however, the low therapeutic index and associated side effects have hindered progress. In response to these challenges, immunocytokines, engineered fusion proteins that combine the specificity of antibodies with the immune-stimulatory properties of cytokines, have been employed to enable targeted delivery of cytokine signals to immune cells or the tumor microenvironment to minimize pathological consequences. Here, we describe SAR445877 (SAR’877), a novel PD-1-targeted immunocytokine that fuses a high-affinity anti-PD-1 antibody with a detuned IL-15/IL-15Rα sushi domain complex. SAR’877 simultaneously blocks PD-1/PD-L1 and PD-1/PD-L2 interactions and delivers IL-15 signals selectively to PD-1+ T cells. This design enhances the proliferation and activation of antigen-experienced CD8⁺ and CD4⁺ T cells, as well as NK cells, while limiting systemic inflammatory cytokine release. Mechanistically, SAR’877 preferentially activates STAT5 signaling in PD-1⁺ lymphocytes and restores effector function in exhausted T cells in vitro. A murine surrogate of SAR’877 accelerated viral clearance and reinvigorated exhausted T cells in the chronic LCMV Clone-13 infection model. In multiple syngeneic tumor models, the surrogate induced robust anti-tumor immunity by expanding cytotoxic CD8⁺ T cells and promoting Th1 polarization. Notably, SAR’877 outperformed combination therapy with anti-PD-1 and untargeted IL-15, underscoring the therapeutic potential of targeted IL-15 delivery to PD-1+ cells. These findings position SAR’877 as a promising next-generation checkpoint immunotherapy that augments efficacy while reducing cytokine-associated toxicities.

2026-04-21 | GSE323389 | GEO

PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.

Project description: Not available

| S-EPMC7098565 | biostudies-literature

Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.

Project description: Not available

| S-EPMC8081209 | biostudies-literature

Calcitriol Inhibits Proliferation and Potentially Induces Apoptosis in B16-F10 Cells.

Project description: Not available

| S-EPMC9083216 | biostudies-literature

Transcriptome analysis of Control and FBXO38 knockdown B16-F10 tumor issue

Project description:F-box only protein 38 (FBXO38), which belongs to SKP1-CUL1-F-box protein (SCF) family, exhibits the ability to mediate Lys48-linked poly-ubiquitination and subsequent proteasome degradations of PD-1.To investigate the effect of FBXO38 knockdown on transcription in tumor, we performed RNA-seq in control and FBXO38 knockdown B16-F10 tumor issue.

2024-02-07 | GSE246258 | GEO

B16-F10 RNA-Seq

Project description:RNA-Seq of B16-F10 mouse melanoma cell line and gene expression profiling

2014-01-31 | E-MTAB-2271 | biostudies-arrayexpress

RNAseq analysis of IL-18 WT- and IL-18 D69A-overexpressing B16-F10 tumors

Project description:To gain insights into the function and mechanism of Interleukin (IL)-18 in cancer cells, we conducted RNA-seq analysis to compare the gene expression profiles between IL-18 WT- and IL-18 D69A (IL-18 mutagenesis replacing aspartate (D) with alanine (A) at position 69)-overexpressing B16-F10 tumors. As expected, many genes were upregulated in IL-18 WT samples. Notably, transcripts related to many signaling pathways such as interferon signaling pathway were significantly enriched in samples expressing IL-18 WT.

2024-12-18 | GSE248478 | GEO

Cytosolic DNA Sensor Upregulation Accompanies DNA Electrotransfer in B16.F10 Melanoma Cells.

Project description: Not available

| S-EPMC5022127 | biostudies-literature